BriaCell Therapeutics Reports Tumor Regression in Phase 2 Study of Bria-IMT for Metastatic Breast Cancer
I'm PortAI, I can summarize articles.
BriaCell Therapeutics Corp. has reported tumor regression in its Phase 2 study of Bria-IMT™ for metastatic breast cancer. New clinical images show regression of metastatic lesions in various locations, with no treatment-related discontinuations reported. The study includes patients previously treated with other therapies. Bria-IMT™ is also in a pivotal Phase 3 trial and has received Fast Track Designation from the US FDA.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments